Volume 15 | March 2024
Classifying Tardive Dyskinesia (TD) and Drug-Induced Parkinsonism (DIP) as EPS Leads to Misdiagnosis and Inappropriate Use of Anticholinergics in TD
This newsletter is produced by Teva Pharmaceuticals, and Dr Chepke was compensated by Teva for his insights.
Expert Commentary
Expert Commentary With Craig Chepke, MD
In this interview, he discusses the outmoded diagnosis “extrapyramidal symptoms” and a recent publication he authored that reported the real-world usage of benztropine in drug-induced movement disorders.
Read more
Past Volumes
Volume 14 - Understanding the Long-Term Nature of TD and Its Impact on the Underlying Mental Health Condition
Read more
Volume 13 - Exploring the Nurse Practitioner's Role in the Screening and Assessment of Patients for Tardive Dyskinesia
Read more
Volume 11 - The Critical Need to Accurately Differentiate Tardive Dyskinesia Versus Drug-Induced Parkinsonism
Read more
Volume 6 - Treatment of Tardive Dyskinesia: Considerations Regarding Metabolic Pathways and Drug-Drug Interactions
Read more